Antioxidative stress compositions, methods of preparing and uses thereof

Abstract

Antioxidative stress compositions, methods of using antioxidative stress composition and methods of preparing antioxidative stress composition compositions are described. The antioxidative stress compositions may be chemopreventive and/or immunomodulatory. Resveratrol, genistein, ellagic acid, curcumin and quercetin may be included in the antioxidative stress composition compositions individually or in any combination.

1 - 46 . (canceled) 
     
     
         47 . A dog biscuit comprising a therapeutically effective amount of a combination comprising at least three active agents selected from the group consisting of resveratrol, genistein, ellagic acid, curcumin, quercetin, prodrugs, metabolites, salts of any of the foregoing, and mixtures of any of the foregoing sufficient to increase production of IL-10 in a dog after once-a-day or twice-a-day administration of the dog biscuit to the dog. 
     
     
         48 . The dog biscuit of  claim 47 , wherein resveratrol comprises from about 1% to about 80% of the combination by weight, ellagic acid comprises from about 0.25% to about 20% of the combination by weight, genistein comprises from about 0.5% to about 40% of the combination by weight, curcumin comprises from about 1% to about 80% of the combination by weight; and quercetin comprises from about 1% to about 80% of the combination by weight. 
     
     
         49 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises from about 0.05 mg to about 2000 mg of resveratrol. 
     
     
         50 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises from about 0.05 mg to about 1000 mg of ellagic acid. 
     
     
         51 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises from about 0.05 mg to about 1000 mg genistein. 
     
     
         52 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises from about 0.05 mg to about 2000 mg curcumin. 
     
     
         53 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises from about 0.05 mg to about 2000 mg quercetin. 
     
     
         54 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises resveratrol and at least two active agents selected from the group consisting of genistein, ellagic acid, curcumin, quercetin, prodrugs, metabolites, salts, and mixtures of any of the foregoing, and provides a serum level of resveratrol of from about 3.86 ng/ml to about 154 μg/ml in the dog after said administration. 
     
     
         55 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises resveratrol and at least two active agents selected from the group consisting of genistein, ellagic acid, curcumin, quercetin, prodrugs, metabolites, salts, and mixtures of any of the foregoing, and provides a serum level of resveratrol-3-O-glucuronide of from about 12.9 ng/ml to about 514 μg/ml in the dog after said administration. 
     
     
         56 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises resveratrol and at least two active agents selected from the group consisting of resveratrol, genistein, ellagic acid, curcumin, quercetin, prodrugs, metabolites, salts, and mixtures of any of the foregoing to provide a serum level of trans-resveratrol-4′-sulfate of from about 8.9 ng/ml to about 355 μg/ml in the dog after said administration. 
     
     
         57 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises resveratrol and at least two active agents selected from the group consisting of genistein, ellagic acid, curcumin, quercetin, prodrugs, metabolites, salts, and mixtures of any of the foregoing and provides a serum level of trans-resveratrol-3-sulfate of from about 84.9 ng/ml to about 3397 μg/ml in the dog after said administration. 
     
     
         58 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises resveratrol and at least two active agents selected from the group consisting of genistein, ellagic acid, curcumin, quercetin, prodrugs, metabolites, salts, and mixtures of any of the foregoing and provides a serum level of cis-resveratrol-3-sulfate of from about 2.7 ng/ml to about 108 μg/ml in the dog after said administration. 
     
     
         59 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises resveratrol and at least two active agents selected from the group consisting of resveratrol, genistein, ellagic acid, curcumin, quercetin, prodrugs, metabolites, salts, and mixtures of any of the foregoing and provides a serum level of resveratrol sulfate total of from about 36.7 ng/ml to about 1467 μg/ml in the dog after said administration. 
     
     
         60 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises genistein and at least two active agents selected from the group consisting of resveratrol, ellagic acid, curcumin, quercetin, prodrugs, metabolites, salts, and mixtures of any of the foregoing and provides a serum level of genistein-4′-glucuronide of from about 14 μg/ml to about 14167 μg/ml in the dog after said administration. 
     
     
         61 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises genistein and at least two active agents selected from the group consisting of resveratrol, ellagic acid, curcumin, quercetin, prodrugs, metabolites, salts, and mixtures of any of the foregoing and provides a serum level of genistein-4′-glucuronide of from about 1.7 μg/ml to about 1700 μg/ml in the dog after said administration. 
     
     
         62 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises genistein and at least two active agents selected from the group consisting of resveratrol, ellagic acid, curcumin, quercetin, prodrugs, metabolites, salts, and mixtures of any of the foregoing to provide a serum level of genistein sulfate of from about 54 μg/ml to about 53836 μg/ml. 
     
     
         63 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises curcumin and at least two active agents selected from the group consisting of resveratrol, genistein, ellagic acid, quercetin, prodrugs, metabolites, salts, and mixtures of any of the foregoing and provides a serum level of curcumin glucuronide of from about 6.25 ng/ml to about 250 μg/ml in the dog after said administration. 
     
     
         64 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises quercetin and at least two active agents selected from the group consisting of resveratrol, genistein, ellagic acid, curcumin, prodrugs, metabolites, salts, and mixtures of any of the foregoing and provides a mean serum level of quercetin of from about 0.2 ng/ml to about 8000 μg/ml. 
     
     
         65 . The dog biscuit of  claim 47 , wherein the dog biscuit comprises resveratrol, genistein, curcumin, quercetin and, after administration to a dog, provides
 (i) a serum level of resveratrol of from about 3.86 ng/ml to about 154 μg/ml;   (ii) a serum level of resveratrol-3-O-glucuronide of from about 12.9 ng/ml to about 514 μg/ml;   (iii) a serum level of trans-resveratrol-4′-sulfate of from about 8.9 ng/ml to about 355 μg/ml;   (iv) a serum level of trans-Resveratrol-3-sulfate of from about 84.9 ng/ml to about 3397 μg/ml;   (v) a serum level of cis-resveratrol-3-sulfate of from about 2.7 ng/ml to about 108 μg/ml;   (vi) a serum level of resveratrol sulfate total of from about 36.7 ng/ml to about 1467 μg/ml;   (vii) a serum level of genistein-4′-glucuronide of from about 14 μg/ml to about 14167 μg/ml;   (viii) a serum level of genistein-4′-glucuronide of from about 1.7 μg/ml to about 1700 μg/ml;   (ix) a serum level of genistein sulfate of from about 54 μg/ml to about 53836 μg/ml;   (x) a mean serum level of curcumin glucuronide of from about 6.25 ng/ml to about 250 μg/ml; and   (xi) a serum level of quercetin of from about 0.2 ng/ml to about 8000 μg/ml.   
     
     
         66 . A dog biscuit comprising a therapeutically effective amount of a combination comprising at least three active agents selected from the group consisting of resveratrol, genistein, ellagic acid, curcumin, quercetin, prodrugs, metabolites, salts of any of the foregoing, and mixtures of any of the foregoing sufficient to increase a number of monocytes and macrophages in a dog after once-a-day or twice-a-day administration of the dog biscuit to the dog.